The Next Generation of Cancer Therapeutics

Theresa Brady
Theresa Brady
May 29, 2020

Our Biotechnology: Beyond Imagination series highlights the technology and scientific advancements of BIO Digital participating companies and BIO member companies. Today’s feature is Sutro Biopharma, a clinical stage company that discovers, develops and manufactures therapeutics for diseases like cancer and autoimmune disorders.

Beyond Imagination Member Spotlight: Sutro Biopharma

Now more than ever, we know the importance of working on tomorrow’s challenges today. While the world battles the novel coronavirus, scientists and researchers continue to work on life-threatening diseases like cancer, Alzheimer’s and heart disease in laboratories across the globe. 

Consider these statistics. A new cancer is diagnosed every 30 seconds. Cancer accounts for one in six deaths around the world. How can we combat this debilitating disease?

Meet Sutro Biopharma, a clinical stage company working to develop the next generation of cancer therapeutics. Using innovative technology, Sutro identifies and tests molecules in a matter of weeks to identify optimal treatments designed for safety, efficacy and potency.

Sutro specializes in Antibody Drug Conjugates (ADCs), powerful, targeted therapies designed to selectively kill cancer cells while minimizing effects on healthy tissue. This method aims to improve overall treatment efficiency and stability by eliminating targeted cells and leaving healthy cells intact.


What’s in the Pipeline?

This year, Sutro unveiled its next generation ADC technology at the World ADC London meeting. The team announced that the technology would include tumor targeting immunostimulatory antibody drug conjugates, IADCs. These IADCs are designed to deliver one drug directly to the tumor that attacks tumor cells while also priming an immune response to the patient’s unique cells. The company believes its IADC approach may create a new therapeutic opportunity by combining the best features of an ADC with the biology of a personalized vaccine.

“Cancer has been a scourge for many, many years for many, many people,” said Bill J. Newell, chief executive officer. “Changing cancer treatments and giving patients longer lives and better quality of life – that’s the mission of Sutro.”

Sutro hosts the world’s only cGMP cell-free manufacturing facility in San Carlos, Calif. As of April 2020, the company manufactures two wholly owned clinical phase products in the facility: TRO-001 for the treatment of multiple myeloma and lymphoma, and STRO-002 for the treatment of ovarian and endometrial cancers.

While the Sutro team works tirelessly to find innovative treatments for cancer, BIO is proud to continue supporting this hardworking team and looks forward to a time when we can improve treatments for cancer and other diseases across the globe.

Registered attendees of BIO Digital can learn more about Sutro Biopharma by attending a session with Sutro’s CEO William Newell: 2020 Vision: Welcoming in a New Decade of Deal-Making. Attendees can also connect with companies like Sutro through BIO’s One-on-One Partnering™ system, educational programming and company presentations.